TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN “ PaxMedica Inc. (Nasdaq: PXMD) (the Company), a leading biopharmaceutical company dedicated to advancing treatments for...
Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nationsAs previously...
The South African Health Products Regulatory Agency (SAHPRA) has approved the application of PaxMedica to commence a Phase IB clinical trial of its therapy, PAX-101 (suramin intravenous (IV) infusions), in individuals with long Covid-19 syndrome (LCS).
PaxMedica has presented additional data and analyses from its Phase II clinical trial evaluating PAX-101 – intravenous (IV) suramin – an investigational drug with a proposed novel mechanism of action, that the company is developing as a potential treatment for the core and related symptoms of autism spectrum disorder (ASD).